Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TMEM97 | Q5BJF2 | 3/20 | 0.64 |
| ▸ | HTR2B | P41595 | 2/20 | 0.64 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.64 |
| ▸ | HTR3B | O95264 | 1/20 | 0.64 |
| ▸ | HTR3A | P46098 | 1/20 | 0.64 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.64 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.64 |
| ▸ | CRBN | Q96SW2 | 13/20 | 0.61 |
| ▸ | DDB1 | Q16531 | 12/20 | 0.61 |
| ▸ | IKZF3 | Q9UKT9 | 3/20 | 0.61 |
| ▸ | TNF | P01375 | 2/20 | 0.61 |
| ▸ | IL1B | P01584 | 2/20 | 0.61 |
| ▸ | IKZF1 | Q13422 | 2/20 | 0.61 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.61 |
| ▸ | HTR2A | P28223 | 1/20 | 0.49 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.49 |
| ▸ | BRD4 | O60885 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9989426 | 1.00 | TMEM97 (0.64) | TMEM97HTR2BHTR3EHTR3BHTR3A | |
| SCHEMBL22845476 | 0.88 | CRBN (0.62) | TMEM97HTR2BHTR3EHTR3BHTR3A | |
| SCHEMBL20129285 | 0.85 | CRBN (0.62) | TMEM97HTR2BHTR3EHTR3BHTR3A | |
| SCHEMBL845412 | 0.84 | CRBN (0.55) | TMEM97HTR2BHTR3EHTR3BHTR3A | |
| SCHEMBL21509694 | 0.84 | CRBN (0.55) | TMEM97HTR2BHTR3EHTR3BHTR3A | |
| SCHEMBL23418195 | 0.82 | DDB1 (0.49) | TMEM97HTR2BHTR3EHTR3BHTR3A | |
| Hydrochloric Acid SCHEMBL31259831 | 0.79 | HTR2B (0.72) | TMEM97HTR2BHTR3EHTR3BHTR3A | |
| SCHEMBL19582762 | 0.77 | CRBN (0.59) | TMEM97HTR2BHTR3EHTR3BHTR3A | |
| SCHEMBL10691837 | 0.77 | TMEM97 (0.70) | TMEM97HTR2BHTR3EHTR3BHTR3A | |
| SCHEMBL28687402 | 0.77 | DDB1 (0.50) | TMEM97HTR2BHTR3EHTR3BHTR3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11541051-B2 | Compositions and methods for treating CDK4/6-mediated cancer | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2023-01-03 | — | — | US | disclosed |
| US-20190336503-A1 | COMPOSITIONS AND METHODS FOR TREATING CDK4/6-MEDIATED CANCER | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI | 2019-11-07 | — | — | US | disclosed |
| EP-2582836-B1 | PRPK-TPRKB MODULATORS AND USES THEREOF | TAIHO PHARMACEUTICAL CO LTD (JP) | 2018-03-07 | — | — | EP | disclosed |
| EP-2582836-B1 | PRPK-TPRKB MODULATORS AND USES THEREOF | TAIHO PHARMACEUTICAL CO LTD (JP) | 2018-03-07 | — | — | EP | disclosed |
| US-9193989-B2 | PRPK-TPRKB modulators and uses thereof | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2015-11-24 | — | — | US | disclosed |
| US-9193989-B2 | PRPK-TPRKB modulators and uses thereof | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2015-11-24 | — | — | US | disclosed |
| US-20110319277-A1 | PRPK-TPRKB MODULATORS AND USES THEREOF | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2011-12-29 | — | — | US | disclosed |
| US-20110319277-A1 | PRPK-TPRKB MODULATORS AND USES THEREOF | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2011-12-29 | — | — | US | disclosed |
| US-20110319277-A1 | PRPK-TPRKB MODULATORS AND USES THEREOF | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2011-12-29 | — | — | US | disclosed |
| WO-2011160042-A2 | PRPK-TPRKB MODULATORS AND USES THEREOF | MAKOTO LIFE SCIENCES, INC. (US) | 2011-12-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190336503-A1 | COMPOSITIONS AND METHODS FOR TREATING CDK4/6-MEDIATED CANCER | CDK4, CDK6, CDK2 | TMEM97 4683/4885HTR2B 3779/4885HTR3E 3069/4885 |
| US-11541051-B2 | Compositions and methods for treating CDK4/6-mediated cancer | CDK4, CDK6, CDK2 | TMEM97 4683/4885HTR2B 3779/4885HTR3E 3069/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.